DE60228082D1 - Nten und neue liganden und pharmazeutische zusammensetzungen - Google Patents

Nten und neue liganden und pharmazeutische zusammensetzungen

Info

Publication number
DE60228082D1
DE60228082D1 DE60228082T DE60228082T DE60228082D1 DE 60228082 D1 DE60228082 D1 DE 60228082D1 DE 60228082 T DE60228082 T DE 60228082T DE 60228082 T DE60228082 T DE 60228082T DE 60228082 D1 DE60228082 D1 DE 60228082D1
Authority
DE
Germany
Prior art keywords
nten
pharmaceutical compositions
new ligands
switches
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60228082T
Other languages
English (en)
Inventor
Kathryn Rene Bracken
Los Angeles Joseph E De
Ying Huang
Michael J Kadan
Gary M Ksander
Dennis B Zerby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60228082D1 publication Critical patent/DE60228082D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60228082T 2001-05-31 2002-05-31 Nten und neue liganden und pharmazeutische zusammensetzungen Expired - Fee Related DE60228082D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29483901P 2001-05-31 2001-05-31
PCT/US2002/016946 WO2002097050A2 (en) 2001-05-31 2002-05-31 Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DE60228082D1 true DE60228082D1 (de) 2008-09-18

Family

ID=23135160

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228082T Expired - Fee Related DE60228082D1 (de) 2001-05-31 2002-05-31 Nten und neue liganden und pharmazeutische zusammensetzungen

Country Status (7)

Country Link
US (1) US7381813B2 (de)
EP (2) EP2060582A1 (de)
JP (1) JP2004537293A (de)
AT (1) ATE403676T1 (de)
AU (1) AU2002303903A1 (de)
DE (1) DE60228082D1 (de)
WO (1) WO2002097050A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
EP2141228A1 (de) * 2001-12-18 2010-01-06 Cancer Research Technology Limited Methode zur Herstellung von proliferierenden und differenzierenden B-Zelllinien
US20070087346A1 (en) * 2003-10-24 2007-04-19 Gennaro Ciliberto Orthogonal gene switches
US8883507B2 (en) * 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
US7709253B2 (en) * 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
US9273115B2 (en) 2009-01-22 2016-03-01 Centre National De La Recherche Scientifique (Cnrs) Method for controlling the biological activity of a protein in a vertebrate cell
AU2017375630B2 (en) * 2016-12-12 2023-12-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
KR102109820B1 (ko) * 2018-04-16 2020-05-12 한양대학교 산학협력단 비스페놀 a와의 결합력이 향상된 돌연변이 에스트로겐 수용체 단백질 및 이를 이용한 박테리아 균주
AU2021273009A1 (en) 2020-05-13 2022-12-15 Bonum Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
KR20240004433A (ko) * 2021-04-06 2024-01-11 센티 바이오사이언시스, 인코포레이티드 Ert2 돌연변이체 및 이의 용도
WO2022216825A1 (en) * 2021-04-06 2022-10-13 Senti Biosciences, Inc. Ert2 mutants and uses thereof
CN116628472A (zh) * 2023-04-28 2023-08-22 哈尔滨工程大学 一种基于特征关联的辐射源个体信号图结构映射方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996496A (en) 1956-06-22 1961-08-15 Central Pharmacal Company Calcium substitution products of dextran
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
EP0258401A4 (de) * 1986-02-20 1989-06-13 California Biotechnology Inc Eukaryotische expression von steroid-rezeptor-proteinen.
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US5534619A (en) * 1993-11-12 1996-07-09 The Board Of Regents Acting On Behalf Of University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
EP0710288B1 (de) 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenovirale vektoren für die behandlung der hämophilie
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5707865A (en) 1994-12-21 1998-01-13 Kohn; Donald B. Retroviral vectors for expression in embryonic cells
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ATE371736T1 (de) 1996-10-29 2007-09-15 Baylor College Medicine Modifizierte steroid-hormon rezeptoren
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
NZ523649A (en) 2000-07-18 2005-02-25 Novartis Ag Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches

Also Published As

Publication number Publication date
AU2002303903A1 (en) 2002-12-09
EP1397382A4 (de) 2005-08-24
WO2002097050A2 (en) 2002-12-05
EP2060582A1 (de) 2009-05-20
US7381813B2 (en) 2008-06-03
JP2004537293A (ja) 2004-12-16
ATE403676T1 (de) 2008-08-15
US20030143559A1 (en) 2003-07-31
EP1397382A2 (de) 2004-03-17
EP1397382B1 (de) 2008-08-06
WO2002097050A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
DE60228082D1 (de) Nten und neue liganden und pharmazeutische zusammensetzungen
DE69317883D1 (de) Neue Sieben-Transmembran-Rezeptor V28
ATE480252T1 (de) Peptidantagonist von zonulin und dessen verwendung
DE69930835D1 (de) Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten
DE69940063D1 (de) Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
ATE360434T1 (de) April rezeptor (bcma) und verwendungen davon
BR9508402A (pt) Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
ATE347553T1 (de) Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
EP1746160A3 (de) Hepatozyt-Wachstumsfaktor-Rezeptor-Antagonisten und deren Anwendung
MA26390A1 (fr) Derives d'acyl-4-carboxyphenyluree, procedes pour les preparer et leur utilisation
ATE389019T1 (de) Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
DZ2887A1 (fr) Dérivés d'azétidine, leur préparation et les médicaments les contenant.
DE60236170D1 (de) Substituierte indeno-ä1,2-cü-isochinolin-derivate und verwendungszwecke dafür
DE69733933D1 (de) Neue Liganden des Neuropeptide Rezeptors HFGAN72
EP2316944A3 (de) Bindungsreagenzien: chimäre Ligand/Rezeptorproteine
HK1025500A1 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
WO2000042031A3 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
AU1178100A (en) Novel g protein-coupled receptor protein, its dna and ligand thereof
DE69806465D1 (de) Eine heteroethynylen-brücke enthaltende bi-aromatische verbindungen und diese enthaltende pharmazeutische und kosmetische zusammensetzungen
WO2002022819A3 (en) Calcium binding proteins
WO2002090544A3 (en) Protein-protein interactions in adipocyte cells (3)
DE602004031355D1 (de) Neue 1,3-disubstituierte azetidinderivate zur verwendung als liganden des 5ht2a-rezeptors
EP1130122A3 (de) Methode zur Detektion von Polymorphismen des humanen EP1-R Gens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee